Literature DB >> 19063963

Genetic susceptibility in Parkinson's disease.

Jose Miguel Bras1, Andrew Singleton.   

Abstract

It is hoped that an understanding of the genetic basis of Parkinson's disease (PD) will lead to an appreciation of the molecular pathogenesis of disease, which in turn will highlight potential points of therapeutic intervention. It is also hoped that such an understanding will allow identification of individuals at risk for disease prior to the onset of motor symptoms. A large amount of work has already been performed in the identification of genetic risk factors for PD and some of this work, particularly those efforts that focus on genes implicated in monogenic forms of PD, have been successful, although hard won. A new era of gene discovery has begun, with the application of genome wide association studies; these promise to facilitate the identification of common genetic risk loci for complex genetic diseases. This is the first of several high throughput technologies that promise to shed light on the (likely) myriad genetic factors involved in this complex, late-onset neurodegenerative disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19063963      PMCID: PMC2768897          DOI: 10.1016/j.bbadis.2008.11.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  69 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

2.  LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients.

Authors:  Daniel Kam Yin Chan; Ping Wing Ng; Vincent Mok; Jonas Yeung; Zhi Ming Fang; Raymond Clarke; Edward Leung; Lawrence Wong
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

3.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Authors:  Demetrius M Maraganore; Mariza de Andrade; Alexis Elbaz; Matthew J Farrer; John P Ioannidis; Rejko Krüger; Walter A Rocca; Nicole K Schneider; Timothy G Lesnick; Sarah J Lincoln; Mary M Hulihan; Jan O Aasly; Tetsuo Ashizawa; Marie-Christine Chartier-Harlin; Harvey Checkoway; Carlo Ferrarese; Georgios Hadjigeorgiou; Nobutaka Hattori; Hideshi Kawakami; Jean-Charles Lambert; Timothy Lynch; George D Mellick; Spiridon Papapetropoulos; Abbas Parsian; Aldo Quattrone; Olaf Riess; Eng-King Tan; Christine Van Broeckhoven
Journal:  JAMA       Date:  2006-08-09       Impact factor: 56.272

4.  Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset.

Authors:  Georgios M Hadjigeorgiou; Georgia Xiromerisiou; Vanessa Gourbali; Kostantinos Aggelakis; Nikolaos Scarmeas; Alexandros Papadimitriou; Andrew Singleton
Journal:  Mov Disord       Date:  2006-04       Impact factor: 10.338

Review 5.  Heterozygosity for a Mendelian disorder as a risk factor for complex disease.

Authors:  E Sidransky
Journal:  Clin Genet       Date:  2006-10       Impact factor: 4.438

6.  Haplotype-specific expression of exon 10 at the human MAPT locus.

Authors:  Tara M Caffrey; Catharine Joachim; Silvia Paracchini; Margaret M Esiri; Richard Wade-Martins
Journal:  Hum Mol Genet       Date:  2006-11-03       Impact factor: 6.150

7.  LRRK2 R1628P increases risk of Parkinson's disease: replication evidence.

Authors:  E K Tan; Louis C Tan; H Q Lim; R Li; M Tang; Yuen Yih; R Pavanni; K M Prakash; S Fook-Chong; Yi Zhao
Journal:  Hum Genet       Date:  2008-09-10       Impact factor: 4.132

8.  Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal.

Authors:  Jose Bras; Coro Paisan-Ruiz; Rita Guerreiro; Maria Helena Ribeiro; Ana Morgadinho; Cristina Januario; Ellen Sidransky; Catarina Oliveira; Andrew Singleton
Journal:  Neurobiol Aging       Date:  2007-12-21       Impact factor: 4.673

9.  Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population.

Authors:  R Myhre; M Toft; J Kachergus; M M Hulihan; J O Aasly; H Klungland; M J Farrer
Journal:  Acta Neurol Scand       Date:  2008-05-15       Impact factor: 3.209

10.  The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population.

Authors:  Chin-Song Lu; Yah-Huei Wu-Chou; Marina van Doeselaar; Erik J Simons; Hsiu-Chen Chang; Guido J Breedveld; Alessio Di Fonzo; Rou-Shayn Chen; Yi-Hsin Weng; Szu-Chia Lai; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2008-08-21       Impact factor: 2.660

View more
  18 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

3.  Impact of infection on risk of Parkinson's disease: a quantitative assessment of case-control and cohort studies.

Authors:  Lei Meng; Liang Shen; Hong-Fang Ji
Journal:  J Neurovirol       Date:  2019-01-10       Impact factor: 2.643

4.  Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease.

Authors:  Guanghua Wu; Jian Huang; Xungang Feng; Aimei Zhang; Jifeng Li; Shuchao Pang; Kejin Gu; Haixin Dong; Junping Zhang; Huijie Gao; Bo Yan
Journal:  Neurochem Res       Date:  2011-06-05       Impact factor: 3.996

5.  Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Authors:  Jesse R McLean; Penelope J Hallett; Oliver Cooper; Michael Stanley; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

Review 6.  Calcium and Parkinson's disease.

Authors:  D James Surmeier; Paul T Schumacker; Jaime D Guzman; Ema Ilijic; Ben Yang; Enrico Zampese
Journal:  Biochem Biophys Res Commun       Date:  2016-08-30       Impact factor: 3.575

Review 7.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

8.  The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.

Authors:  Barry Rosenbloom; Manisha Balwani; Jeff M Bronstein; Edwin Kolodny; Swati Sathe; Andrea R Gwosdow; John S Taylor; J Alexander Cole; Ari Zimran; Neal J Weinreb
Journal:  Blood Cells Mol Dis       Date:  2010-11-10       Impact factor: 3.039

Review 9.  The link between the GBA gene and parkinsonism.

Authors:  Ellen Sidransky; Grisel Lopez
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

Review 10.  The PARL family of mitochondrial rhomboid proteases.

Authors:  R Blake Hill; Luca Pellegrini
Journal:  Semin Cell Dev Biol       Date:  2010-01-04       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.